Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
By Angelica Peebles,
CNBC
| 02. 21. 2025
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday, marking the end of the Bluebird’s fall from the one of the buzziest biotech firms to one that was on the cusp of running out of money.
Bluebird’s shareholders will receive $3 per share with the possibility of getting another $6.84 a share if Bluebird’s gene therapies reach $600 million in sales in any 12-month period by the end of 2027. Bluebird shares closed at $7.04 on Thursday. They fell 40% on Friday after the company announced the sale.
For more than thirty years, Bluebird has been at the forefront of creating one-time treatments that promised to cure genetic diseases. At one point, Bluebird’s market cap hovered around $9 billion as investors bought into the idea that the company could find success with its gene therapies. It’s fallen under $41 million after the company faced several scientific setbacks, separated its cancer work into another company and fell into financial despair.
The turning point came in 2018, when Bluebird...
Related Articles
President Trump scored a bunch of generally favorable mainstream headlines recently by announcing that he was ordering expanded access to in vitro fertilization (IVF). He had announced in October that he was “the father of IVF” although he also said he had only just learned what it was from Senator Katie Britt (R-AL), who explained it to him over the phone. “And within about two minutes, I understood it.”
The executive order, as reporter Susan Rinkunas wryly noted at...
By Staff, The Economist | 02.21.2025
One of the greatest scandals in modern science began with a late-2010s advertisement for HIV-positive couples looking to have children through in-vitro fertilisation (IVF). The ad had been put out by a scientist named He Jiankui, a biologist then at...
By Oriol Güell, El País | 02.17.2025
A “small strand of blood in the poop.” This was the first sign, initially viewed as unimportant, that put Jesús Lunar and Cristina López on the trail that something was happening with their son’s health. Javier had been born on...
By Bertha Coombs, CNBC | 02.18.2025
Starting in his early teens, Deshawn “DJ” Chow wasn’t sure he’d ever be able to live a normal life. Crushing pain episodes brought on by his sickle cell disease were getting progressively worse.
“It’s just been hard skipping school...
